drugset / Trial / NCT02897830
Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
Phase 2
Terminated
46 enrolled
University Hospital, Toulouse
Celgene Corporation · collabTakeda · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label study to evaluate the safety and efficacy of Ixazomib in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma (MM). The patient population will consist of adult men and women up to 65 years, who have a confirmed diagnosis of MM who meet eligibility criteria.
Timeline
- Start
- 2016-08-05
- Primary completion
- 2018-11
- Completion
- 2020-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Ixazomib | Unknown | 4 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |